A RANDOMISED CONTROLLED TRIAL TO COMPARE THE INCIDENCE OF SYMPTOMATIC AND ASYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS FOLLOWING PELVI-ACETABULAR SURGERY IN PATIENTS RECEIVING DIFFERENT THROMBOPROPHYLAXIS

A RANDOMISED CONTROLLED TRIAL TO COMPARE THE INCIDENCE OF SYMPTOMATIC AND ASYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS FOLLOWING PELVI-ACETABULAR SURGERY IN PATIENTS RECEIVING DIRECT ORAL ANTI COAGULANTS(DOAC) AND THE PATIENTS RECEIVING LOW MOLECULAR WEIGHT HEPARIN(LMWH) AS CHEMOPROPHYLAXIS - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2024/03/063990

Enrollment

100

Registered

2024-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S324- Fracture of acetabulum

Interventions

Intervention1: enoxarparin injection: postoperatively giving enoxaparin injection 0.4 ml once daily for 28 days Control Intervention1: rivaroxaban: Postoperatively rivaroxaban tablets 10 mg once daily

Eligibility

Inclusion criteria

Inclusion criteria: Patients having pelvis or acetabular fracture

Exclusion criteria

Exclusion criteria: Patients with renal failure,sepsis ,allergic to dye Patients with history of malignant primary or metastatic tumors Open fractures or fractures involving lower limb Associated Head and Spine injury and abdominal trauma Associated vascular injury requiring high dose anticoagulant Fracture due to pathological bone lesion at local site. Are on long-term anticoagulants. Have been diagnosed with a VTE within the last 6 months. Are on therapeutic, as opposed to prophylactic, anticoagulants at the time of admission. Have an allergy to aspirin or non-steroidal antiinflammatory drugs, or a history of heparin-induced thrombocytopenia, or other medical contraindication to anticoagulants

Design outcomes

Secondary

Measure	Time frame
percentage of vte in different surgicl approachTimepoint: 6 weeks	—

Primary

Measure	Time frame
percentage of postoperatively symptomatic and asymptomatic venous thromboembolic eventsTimepoint: 6 weeks	—

Countries

India

Contacts

Public ContactDr Tanish Bansal

AIIMS JPNATC

Drvijaysharmatrauma@gmail.com7073259591

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026